Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EQCVE:GPHNASDAQ:MDNANYSE:RGC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEQEquillium$0.44-6.7%$0.63$0.36▼$1.89$15.66M1.87360,588 shs66,992 shsGPHGraphite OneC$0.92-4.2%C$0.94C$0.55▼C$1.07C$93.15M1.0258,545 shs27,159 shsMDNAMedicenna Therapeutics$0.29$0.15▼$0.84$10.93M1.3160,047 shs1.27 million shsRGCRegal Entertainment Group$29.10+498.8%$0.00$3.03▼$69.00$53.35M-0.59265,168 shs2,031 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEQEquillium0.00%-7.24%-10.18%-35.99%-75.51%GPHGraphite One0.00%0.00%-5.15%+12.20%+17.95%MDNAMedicenna Therapeutics0.00%0.00%0.00%0.00%0.00%RGCRegal Entertainment Group0.00%+1.67%-16.09%+506.88%+482.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEQEquillium2.7733 of 5 stars3.25.00.00.02.41.70.6GPHGraphite OneN/AN/AN/AN/AN/AN/AN/AN/AMDNAMedicenna Therapeutics1.2395 of 5 stars3.50.00.00.00.01.70.0RGCRegal Entertainment GroupN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEQEquillium 2.33Hold$3.00584.46% UpsideGPHGraphite One 0.00N/AN/AN/AMDNAMedicenna Therapeutics 3.00Buy$2.50∞ UpsideRGCRegal Entertainment Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RGC, GPH, MDNA, and EQ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025EQEquilliumLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/28/2025EQEquilliumLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$3.00 ➝ $1.00(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEQEquillium$41.10M0.38N/AN/A$0.64 per share0.68GPHGraphite OneN/AN/AC$0.01 per share94.17C$0.44 per shareN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/A$0.32 per shareN/ARGCRegal Entertainment GroupN/AN/AN/AN/A$0.63 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEQEquillium-$13.34M-$0.23N/AN/AN/A-10.05%-20.68%-10.77%5/8/2025 (Estimated)GPHGraphite One-C$4.90M-C$0.07N/A∞N/AN/A-10.96%-6.61%N/AMDNAMedicenna Therapeutics-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/ARGCRegal Entertainment Group-$4.30MN/A0.00∞N/AN/AN/AN/AN/ALatest RGC, GPH, MDNA, and EQ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025EQEquillium-$0.23N/AN/AN/AN/AN/A3/27/2025Q4 2024EQEquillium-$0.22-$0.16+$0.06-$0.16N/A$4.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEQEquilliumN/AN/AN/AN/AN/AGPHGraphite OneN/AN/AN/AN/AN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/ARGCRegal Entertainment GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEQEquilliumN/A3.043.04GPHGraphite One0.021.090.33MDNAMedicenna TherapeuticsN/A9.579.57RGCRegal Entertainment GroupN/A41.9241.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEQEquillium27.05%GPHGraphite One0.07%MDNAMedicenna Therapeutics12.38%RGCRegal Entertainment Group0.13%Insider OwnershipCompanyInsider OwnershipEQEquillium30.30%GPHGraphite One28.81%MDNAMedicenna Therapeutics33.10%RGCRegal Entertainment Group2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEQEquillium4035.72 million24.70 millionNot OptionableGPHGraphite One20101.25 millionN/ANot OptionableMDNAMedicenna Therapeutics1669.64 million46.59 millionNot OptionableRGCRegal Entertainment GroupN/A13.01 million12.75 millionNot OptionableRGC, GPH, MDNA, and EQ HeadlinesRecent News About These CompaniesRGC Resources: Worth Watching For A Good Entry PointApril 10, 2025 | seekingalpha.comCircle Centre movie theatre, Regal UA, permanently closesNovember 6, 2024 | msn.comRegal UA Circle Centre movie theater closes after 29 yearsNovember 4, 2024 | ibj.com‘Open Enrollment: What You Need to Know,’ with Mindy Morgen of Regal Medical GroupOctober 14, 2024 | sandiegouniontribune.comRegal Cinema and Cinemark upgradesSeptember 24, 2024 | yahoo.comAMC, Regal investing $2.2B to upgrade movie theater experienceSeptember 21, 2024 | msn.comRegal Inks Multiyear Deal With Fandango On Advertising, Concessions SalesAugust 27, 2024 | msn.comSoleil Film's ``All That I Need'' to be Theatrically Released this November in Regal Cinemas, United Artists Theatres and EdwardAugust 17, 2024 | br.advfn.comRegal matriarch 'Mother Lily' Monteverde diesAugust 6, 2024 | philstar.comMother Lily Monteverde, Regal Entertainment matriarch, passes awayAugust 6, 2024 | gmanetwork.comMother Lily Monteverde, Regal Entertainment matriarch and star-maker, dead at 85August 6, 2024 | entertainment.inquirer.netRGC Theatre To Present First Regional Workshop Of GRACE AND THE GHOSTAugust 1, 2024 | broadwayworld.comWhat Is Going on With Regencell Bioscience (RGC) Stock Today?July 23, 2024 | investorplace.comLocal investors buy shuttered Woodway cinema with vision of sports entertainmentJuly 19, 2024 | wacotrib.comEric Bischoff – ‘William Regal Joined WCW When It Was Sh*tstorm’May 27, 2024 | ewrestlingnews.comRegal Hires Exhibition Vet Rob Westerling As SVP U.S. ContentMay 16, 2024 | msn.comOld Regal theater at Music City Mall in Odessa transforming into an Urban Air ParkMay 8, 2024 | msn.comEarly Bird weekend savings arrive at Regal CinemasMay 4, 2024 | msn.comCompany History - Regal Entertainment and ConsultantsMay 1, 2024 | moneycontrol.comThis LGBTQ film fest returns to Mia mi with free Uber rides to theaters for screeningsApril 17, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRGC, GPH, MDNA, and EQ Company DescriptionsEquillium NASDAQ:EQ$0.44 -0.03 (-7.02%) As of 04/25/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Graphite One CVE:GPHC$0.92 -0.04 (-4.17%) As of 04/25/2025 03:59 PM EasternGraphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.Medicenna Therapeutics NASDAQ:MDNAMedicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.Regal Entertainment Group NYSE:RGCRegal Entertainment Group is an operator of theatre circuits in the United States. As of March 31, 2017, the Company operated 7,262 screens in 559 theatres in 43 states along with Guam, Saipan, American Samoa and the District of Columbia. The Company manages its business under theatre exhibition operations segment. The Company develops, acquires and operates multi-screen theatres primarily in mid-sized metropolitan markets and suburban growth areas of metropolitan markets throughout the United States. The Company operates multi-screen theatres. The Company is the parent company of Regal Entertainment Holdings, Inc. (REH), which is the parent company of Regal Cinemas Corporation (Regal Cinemas) and its subsidiaries. Regal Cinemas' subsidiaries include Regal Cinemas, Inc. (RCI) and its subsidiaries, which include Edwards Theatres, Inc. (Edwards), Regal CineMedia Corporation (RCM) and United Artists Theatre Company (United Artists). More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
